Last edition
News about "small cell lung cancer"
Ifinatamab Deruxtecan Gets US Priority Review for Small Cell Lung Cancer
Ifinatamab deruxtecan receives US Priority Review for Small Cell Lung Cancer, supported by Phase 2 data, with potential as a first-in-class B7-H3 targeted Antibody Drug Conjugate.
Small Cell Lung Cancer | 13/04/2026 | By News Bureau | 148
The collaboration between Boehringer Ingelheim and BioNTech will evaluate a dual immuno-oncology approach in extensive-stage small cell lung cancer, aiming to improve outcomes in a disease with limited treatment options.
Small Cell Lung Cancer | 11/04/2026 | By News Bureau | 107
GSK plc Secures Japan Orphan Drug Status for Ris-Rez in Small-Cell Lung Cancer
Japan’s health ministry grants orphan drug designation to GSK’s investigational ADC Ris-Rez for SCLC, supported by early clinical data showing durable responses in advanced-stage patients.
Small-Cell Lung Cancer | 24/03/2026 | By News Bureau | 130
Intas Pharmaceuticals has launched HETRONIFLY (Serplulimab), the world’s first PD-1 inhibitor approved for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in the Indian market.
Small Cell Lung Cancer | 06/08/2025 | By Mrinmoy Dey | 411
Amgen Reports Positive Interim Results for IMDELLTRA in Small Cell Lung Cancer Study
IMDELLTRA demonstrated statistically significant and clinically meaningful improvement in overall survival compared to local standard-of-care chemotherapy.
Small Cell Lung Cancer | 14/04/2025 | By Abha | 530
Phanes Secures Fast Track Designation for PT217 from FDA
PT217, a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD47, is being developed for the treatment of patients with small cell lung cancer (SCLC) and neuroendocrine carcinoma, including neuroendocrine prostate cancer (NEPC).
Small Cell Lung Cancer | 05/12/2024 | By Aishwarya | 355
FDA Approves Amgen's IMDELLTRA for Advanced Small Cell Lung Cancer
The approval is based on the encouraging response rate and duration of response (DoR) observed in clinical studies, under the FDA's accelerated approval pathway.
Small Cell Lung Cancer | 17/05/2024 | By Abha | 845
SN Bioscience's SNB-101 Granted FDA Fast Track Designation for Small Cell Lung Cancer Treatment
SNB-101, previously designated as an orphan drug for SCLC and pancreatic cancer, has now received Fast Track designation, signaling a step towards potential commercialization following the completion of phase 2 clinical trials.
Small Cell Lung Cancer | 10/05/2024 | By Abha | 663
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy